Alkermes (NASDAQ:ALKS) Price Target Raised to $43.00

Alkermes (NASDAQ:ALKS) had its price objective lifted by Wells Fargo & Company from $37.00 to $43.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective would suggest a potential upside of 42.51% from the stock’s current price.

Several other analysts have also issued reports on the company. Needham & Company LLC increased their target price on Alkermes from $43.00 to $44.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Royal Bank Of Canada cut their price objective on shares of Alkermes from $47.00 to $45.00 and set an “outperform” rating for the company in a research report on Thursday. HC Wainwright reissued a “neutral” rating and issued a $43.00 target price on shares of Alkermes in a report on Thursday. Wall Street Zen cut shares of Alkermes from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 9th. Finally, Deutsche Bank Aktiengesellschaft reduced their price target on shares of Alkermes from $55.00 to $45.00 and set a “buy” rating on the stock in a research report on Thursday, November 13th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Alkermes presently has an average rating of “Moderate Buy” and an average target price of $44.07.

Alkermes Stock Down 2.8%

Shares of ALKS traded down $0.87 during mid-day trading on Thursday, hitting $30.17. 745,544 shares of the company’s stock were exchanged, compared to its average volume of 2,004,099. Alkermes has a 52 week low of $25.17 and a 52 week high of $36.32. The stock’s 50-day simple moving average is $31.44 and its 200-day simple moving average is $30.17. The firm has a market cap of $4.98 billion, a price-to-earnings ratio of 14.94 and a beta of 0.49.

Alkermes (NASDAQ:ALKS) last issued its quarterly earnings results on Wednesday, February 25th. The company reported $0.29 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by ($0.14). Alkermes had a net margin of 22.27% and a return on equity of 21.81%. The company had revenue of $384.55 million during the quarter, compared to the consensus estimate of $380.44 million. During the same quarter last year, the firm posted $1.05 earnings per share. The company’s quarterly revenue was down 10.6% on a year-over-year basis. Alkermes has set its FY 2026 guidance at -0.798–0.680 EPS. Analysts forecast that Alkermes will post 1.31 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Craig C. Hopkinson sold 9,000 shares of Alkermes stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $33.93, for a total transaction of $305,370.00. Following the sale, the executive vice president directly owned 57,740 shares in the company, valued at $1,959,118.20. This trade represents a 13.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Shane Cooke sold 61,200 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $34.57, for a total transaction of $2,115,684.00. Following the sale, the director directly owned 103,744 shares in the company, valued at $3,586,430.08. The trade was a 37.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 148,148 shares of company stock worth $5,028,378 in the last 90 days. 4.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Alkermes

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. T. Rowe Price Investment Management Inc. bought a new position in Alkermes during the 4th quarter worth $59,000. Mercer Global Advisors Inc. ADV bought a new stake in shares of Alkermes in the 4th quarter valued at about $256,000. Summit Global Investments grew its position in shares of Alkermes by 48.8% in the 4th quarter. Summit Global Investments now owns 29,662 shares of the company’s stock valued at $830,000 after buying an additional 9,724 shares during the last quarter. Vident Advisory LLC increased its stake in shares of Alkermes by 1.1% in the fourth quarter. Vident Advisory LLC now owns 82,294 shares of the company’s stock valued at $2,303,000 after buying an additional 864 shares during the period. Finally, Empowered Funds LLC bought a new position in shares of Alkermes during the fourth quarter worth about $1,712,000. 95.21% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Alkermes

Here are the key news stories impacting Alkermes this week:

• Positive Sentiment: Wolfe Research initiated coverage with an “Outperform” rating and a $45 price target, signaling analyst conviction in upside versus the current level. Wolfe Research initiates coverage of Alkermes (ALKS) with outperform recommendation
• Neutral Sentiment: Alkermes announced a CEO succession plan: long‑time CEO Richard Pops will retire effective July 31, 2026 and EVP/COO Blair Jackson will become CEO on Aug. 1, 2026; Pops will remain chairman — provides leadership clarity but raises integration/execution questions ahead of the Avadel integration. Alkermes plc Announces CEO Succession Plan
• Neutral Sentiment: Company is presenting at upcoming conferences (TD Cowen) and recently closed the Avadel transaction, items investors should watch for slides/management commentary on integration and revenue contribution. Alkermes to Present at the TD Cowen 46th Annual Health Care Conference
• Negative Sentiment: Q4 results: Alkermes reported EPS of ~$0.29, below consensus (~$0.43) while revenue (~$384.6M) was roughly in line/slightly ahead of estimates but down ~10.6% year‑over‑year — an earnings miss that weighs on near‑term investor sentiment. Alkermes plc (NASDAQ:ALKS) Q4 2025 Earnings Call Transcript
• Negative Sentiment: FY‑2026 guidance was updated to a negative EPS range (‑0.798 to ‑0.680), far below Street expectations (consensus ~1.63), creating significant near‑term earnings uncertainty and likely driving most of the downward price pressure. Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026
• Neutral Sentiment: Short‑interest data reported in some feeds appears inconsistent/invalid (zero/NaN values) and shouldn’t be relied on for a constructive signal today. Listen to Conference Call / View Press Release

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.